CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study

Abstract Background Tamoxifen treatment greatly reduces a woman’s risk of developing a second primary breast cancer. There is, however, substantial variability in treatment response, some of which may be attributed to germline genetic variation. CYP2D6 is a key enzyme in the metabolism of tamoxifen...

詳細記述

書誌詳細

主要な著者:	Jennifer D. Brooks, Elizabeth A. Comen, Anne S. Reiner, Irene Orlow, Siok F. Leong, Xiaolin Liang, Lene Mellemkjær, Julia A. Knight, Charles F. Lynch, Esther M. John, Leslie Bernstein, Meghan Woods, David R. Doody, The WECARE Study collaborative group, Kathleen E. Malone, Jonine L. Bernstein
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMC 2018-12-01
シリーズ:	Breast Cancer Research
主題:	Contralateral breast cancer Tamoxifen CYP2D6
オンライン･アクセス:	http://link.springer.com/article/10.1186/s13058-018-1083-y
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!